Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (NCT07169578) titled 'A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease' on Sept. 10.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Hoffmann-La Roche
Condition:
Alzheimers Disease
Intervention:
Drug: Trontinemab
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: October 27, 2025
Target Sample Size: 800
Countries of Recruitment:
United States
Canada
United States
To know more, visit http...